Full Press Release Details
| Elanco Animal Health | |
| 2500 Innovation Way | |
| Greenfield, IN 46140 |
Investor Contact: Kathryn Grissom, +1.317.273.9284,
Media Contact: Colleen Parr Dekker, +1.317.989.7011, colleen.dekker@elancoah.com
Joele Frank: Kelly Sullivan
/ Adam Pollack (212) 355-4449
Elanco Appoints Two Animal
Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors
New Directors Join the Board's
Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora
GREENFIELD, Ind. (DATE) - Elanco Animal Health Incorporated
(NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors
(the "Board"), effective immediately, expanding the Board to 14 members.
Ms. Turner brings significant global experience in both the
animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Laboratories, including most recently
as Chief Marketing Officer, and served in various roles of increasing responsibility at Abbott Laboratories. Mr. Wallace is a well-respected
animal health leader with more than 30 years of executive experience at companies such as Fort Dodge Animal Health, Trupanion and Ceva.
Elanco Chairman R. David Hoover said, "We are pleased to
have reached an agreement with Ancora on a constructive path forward, and we look forward to working with Kathy and Craig toward our
common goal of progressing our robust and innovative pipeline and driving near- and long-term sustainable growth and value for our
Ms. Turner and Mr. Wallace also joined the Board's Finance,
Strategy and Oversight Committee, which has been renamed to better reflect its charter and mandate.
"We are pleased to welcome Kathy and Craig, both accomplished
animal health industry executives, to the Elanco Board," said Jeff Simmons, President and CEO of Elanco Animal Health. "We
are making meaningful progress as we continue to execute our Innovation, Portfolio and Productivity strategy, and we are confident that
Kathy and Craig will be valuable additions to the Board."
Frederick DiSanto, Chairman and Chief Executive Officer of Ancora
Holdings Group LLC, added: "After recent engagement with Elanco, we have aligned on a constructive agreement that adds two pet
healthcare experts to the Board and one of its key committees focused on strategic planning. Craig and Kathy are proven industry operators
with experience that can support ongoing efforts to advance the high-quality pipeline assembled by management. Our recent interactions
with Elanco give us confidence that Jeff and the Board are focused on the right steps with respect to corporate governance and value
In connection with today's announcement, the Company has
entered into a Cooperation Agreement with Ancora Holdings Group LLC and its affiliates that contains customary standstill, voting
and other provisions. The agreement will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.
Kathy Turner held senior leadership positions in international
commercial operations at IDEXX Laboratories (NASDAQ: IDXX), a global pet healthcare innovation company, from 2014 to 2023, including most
recently serving as Chief Marketing Officer. She brings deep understanding of veterinary clinic operations through her tenure with IDEXX.
In her nearly 30-year tenure at Abbott Laboratories (NYSE: ABT), a multinational medical devices and healthcare company, she held multiple
leadership positions, most recently leading commercial operations for Europe. She is currently on the Board of Veterinarians Without Borders,
an organization that promotes animal well-being, human health and economic development domestically and internationally.
Craig Wallace is President of C.S. Wallace Investments & Strategy,
LLC, an animal health and human healthcare investment firm. Mr. Wallace previously served as Chief Executive Officer (North America/Pacific)
of Ceva Sant Animale, the fifth largest animal health company worldwide. He also held leadership roles at Trupanion, Inc. (NASDAQ:
TRUP), a pet insurance provider, and Fort Dodge Animal Health, a global manufacturer of animal health products for the livestock, companion
animal, equine, swine and poultry industries. Additionally, he served on various boards of directors including the National Commission
on Veterinary Economic Issues and the Kansas City Animal Health Corridor Advisory Board. He currently serves on the Board of Directors
of 1C, a pet retail distributor, and KeraVet Bio, a veterinary wound care company.
Elanco Animal Health Incorporated
(NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat
disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With
nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care,
while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and
Companionship Enriching Life and our Elanco Healthy Purpose Sustainability Initiatives - all to advance the health of
animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of the federal securities laws, including, without limitation, statements concerning future business activities
and financial performance, and may be identified by the use of words like "may," "will,"
"could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "estimate," "project," "consider,"
"predict," "potential," "feel," or other comparable terminology. Forward-looking statements are
based on our current expectations and assumptions regarding our business, the economy and other future conditions and are subject to
inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ
materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to
differ materially from those in the forward-looking statements include but are not limited to the following: operating in a highly
competitive industry; the success of our research and development (R&D) and licensing efforts; the impact of disruptive
innovations; competition from generic products; an outbreak of infectious disease carried by farm animals; risks related to the
evaluation of animals; consolidation of our customers and distributors; the impact of increased or decreased sales into our
distribution channels; our dependence on the success of our top products; our ability to complete acquisitions and divestitures and
successfully integrate the businesses we acquire, including the proposed divestiture of our aqua business; our ability to implement
our business strategies or achieve targeted cost efficiencies and gross margin improvements; manufacturing problems and capacity
imbalances; fluctuations in inventory levels in our distribution channels; ; the impact of weather conditions, including those
related to climate change, and the availability of natural resources; the effects of a human disease outbreak, epidemic, pandemic or
other widespread public health concern; the loss of key personnel or highly skilled employees; adverse effects of labor disputes,
strikes and/or work stoppages; the effect of our substantial indebtedness on our business; changes in interest rates; risks related
to the write-down of goodwill or identifiable intangible assets; the lack of availability or significant increases in the cost of
raw materials; risks related to our presence in foreign markets; risks related to currency rate fluctuations; risks related to
underfunded pension plan liabilities; the potential impact that actions by activist shareholders could have on the pursuit of our
business strategies; risks related to certain governance provisions in our constituent documents; actions by regulatory bodies,
including as a result of their interpretation of studies on product safety; the possible slowing or cessation of acceptance and/or
adoption of our farm animal sustainability initiatives; the impact of increased regulation or decreased governmental financial
support related to the raising, processing or consumption of farm animals; the impact of litigation, regulatory investigations, and
other legal matters, including the risk to our reputation; challenges to our intellectual property rights or our alleged violation
of rights of others; misuse, off-label or counterfeiting use of our products; unanticipated safety, quality or efficacy concerns and
the impact of identified concerns associated with our products. For additional information about these and other factors that could
cause actual results to differ materially from forward-looking statements, please see the Risk Factors in the company's latest Form
10-K and Form 10-Qs filed with the Securities and Exchange Commission. Although we have attempted to identify important risk
factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause
actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in
this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. We undertake
no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.